Timeline
Pharma
Imaging Biometrics publishes Phase 1 gallium trial and reopens access programme
Zephyr Energy clears pipeline inspection and starts regulatory push to export Paradox gas
GSK to buy Nuvalent for $10.6bn to add late‑stage lung‑cancer drugs
Aptamer Group launches Gates Foundation‑backed programme to build rapid folate test
Health & Bio Today: Incanthera acquires Énielle skincare brand, Crism Therapeutics, Eco Animal Health
ECO Animal Health renews £10m rolling credit and £5m overdraft
Pennant launches major Auxilium update for "future‑ready foundation"
Novo Nordisk launches Wegovypill in the UAE
Health & Bio Today: ValiRx walks away from Stingray licence, Verici Dx, Inspiration Healthcare, Hammerson
ValiRx shares tumbled after Stingray evaluation ends
Oxford Biomedica's investor day can kick of a rerating and reignite sentiments
Elementis shares up on sale of pharmaceutical manufacturing business
Hammerson prices EUR350m five-year bond and extends credit facilities
Health & Bio Today: Avacta reports positive salivary gland cancer data, hVIVO, ValiRx, CRISM Therapeutics, ProBiotix Health
hVIVO signs consultancy deal with Decoy Therapeutics to advance multi‑virus antivirals
Applied Nutrition shares bulk up on acquisition and Mondelēz collab
CRISM Therapeutics lands Northern Ireland grant for ChemoSeed prostate programme
ValiRx exercises RNA option after evaluation finishes four months early
Health & Bio Today: CelLBxHealth wins AstraZeneca services deal, Avacta Group, AstraZeneca
CelLBxHealth shares rocket on AstraZeneca master services agreement
AstraZeneca wins US approval for Imfinzi in early high‑risk bladder cancer
Health & Bio Today: GSK, BSF Enterprise, Nuformix, Physiomics, SkinBioTherapeutics, Property Franchise Group
GSK posts positive Phase 3 results for Hepatitis B treatment
Physiomics builds hantavirus translational modelling framework
Nuformix results highlight progress as it advances 'viable and attractive' candidates
Health & Bio Today: ImmuPharma narrows loss with P140 partnership push, Physiomics, ValiRx, AstraZeneca
ImmuPharma narrows loss, highlights post-period fundraise
Physiomics secures more modelling and data-science contracts
ValiRx's Cytolytix secures European patent for nanoparticle delivery
AstraZeneca says FDA extends decision date for camizestrant, allowing extra data review
Health & Bio Today: Genedrive chairman exits as Nugent joins board, Novo Nordisk, Crism, Diaceutics, CVS Group, AstraZeneca,
Novo Nordisk study finds two in five high‑risk cardiovascular patients have persistent inflammation
The Premarket Brief: Sound Energy sells Tendrara stake for $57m, CVS Group, Arrow Exploration, AstraZeneca, Atalaya Mining
AstraZeneca wins CHMP backing for Enhertu tumour‑agnostic approval
Health & Bio Today: EMV Capital spotlights XF-73 ahead of Phase 3, IXICO, Oxford Nanopore, AstraZeneca
Broker calls AstraZeneca pipeline news “frenetic”, repeats Sell rating
EMV Capital commercial update spotlights XF-73 as it moves toward Phase 3
IXICO wins £1.3m Alzheimer's and Huntington's clinical analytics contracts
4basebio wins opDNA supply deal for Phase II immunotherapy trial
Big Pharma's AI arms race intensifies as Bristol Myers Squibb hands Anthropic the keys to the enterprise
Health & Bio Today: AstraZeneca wins dual FDA approvals, Advanced Medical Solutions, CelLBxHealth, GSK
CelLBxHealth to deploy Parsortix with AdventHealth for two US clinical studies
ValiRx raises up to £1.155m to fund McGill in‑licence, Cytolytix preclinical work and animal‑health expansion
GSK lands expanded approval for RSV vaccine Arexvy in Japan
AstraZeneca secures US approval for blood pressure drug Baxfendy
AstraZeneca's breast cancer drug Enhertu cleared by FDA
AstraZeneca says Imfinzi plus enfortumab vedotin improves survival in muscle‑invasive bladder cancer
Poolbeg to present POLB 001 CRS data at EHA
Health & Bio Today: Adaptix wins CE mark for Ortho350, Physiomics, IXICO, Novo Nordisk
More in Healthcare
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.
Companies in Pharma
- AstraZeneca AZN
- GSK LSE:GSK
- Bsf Enterprise LSE:BSFA
- Seagate Technology AIM:STX
- Solvonis Therapeutics LSE:SVNS
- Eco Animal Health AIM:EAH
- Novo Nordisk NVO
- Beximco Pharmaceuticals LSE:BXP
- Nuformix LSE:NFX
- Hikma Pharmaceuticals LSE:HIK
- Novo Nordisk A/S 0QIU
- Avere Therapeutics Nasdaq:AVRX
- Eli Lilly NYSE:LLY
- Kailera Nasdaq:KLRA